ATE131871T1 - Rezeptoren für tumornekrosisfaktor-alpha und - beta - Google Patents

Rezeptoren für tumornekrosisfaktor-alpha und - beta

Info

Publication number
ATE131871T1
ATE131871T1 AT90309875T AT90309875T ATE131871T1 AT E131871 T1 ATE131871 T1 AT E131871T1 AT 90309875 T AT90309875 T AT 90309875T AT 90309875 T AT90309875 T AT 90309875T AT E131871 T1 ATE131871 T1 AT E131871T1
Authority
AT
Austria
Prior art keywords
necrosis factor
tumor necrosis
factor alpha
beta receptors
tnf receptors
Prior art date
Application number
AT90309875T
Other languages
English (en)
Inventor
Craig A Smith
Raymond G Goodwin
Patricia M Beckmann
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27410621&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE131871(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE131871T1 publication Critical patent/ATE131871T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT90309875T 1989-09-11 1990-09-10 Rezeptoren für tumornekrosisfaktor-alpha und - beta ATE131871T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40537089A 1989-09-11 1989-09-11
US42141789A 1989-10-13 1989-10-13
US07/523,635 US5395760A (en) 1989-09-05 1990-05-10 DNA encoding tumor necrosis factor-α and -β receptors

Publications (1)

Publication Number Publication Date
ATE131871T1 true ATE131871T1 (de) 1996-01-15

Family

ID=27410621

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90309875T ATE131871T1 (de) 1989-09-11 1990-09-10 Rezeptoren für tumornekrosisfaktor-alpha und - beta

Country Status (9)

Country Link
US (2) US5395760A (de)
EP (1) EP0418014B1 (de)
AT (1) ATE131871T1 (de)
DE (2) DE10075011I2 (de)
DK (1) DK0418014T3 (de)
ES (1) ES2080809T4 (de)
GR (1) GR3019333T3 (de)
LU (1) LU90591I2 (de)
NL (1) NL300008I2 (de)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US6479632B1 (en) * 1988-09-12 2002-11-12 Yeda Research And Development Co. Ltd. Tumor necrosis factor inhibitory protein and its purification
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
DK0393438T3 (da) * 1989-04-21 2005-05-30 Amgen Inc TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US7264944B1 (en) * 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6262239B1 (en) 1989-05-18 2001-07-17 Yeda Research And Development Co., Ltd. TNF receptor-specific antibodies
ES2072330T5 (es) * 1989-05-18 2013-06-24 Yeda Research And Development Co., Ltd. Proteínas de unión II al Factor de Necrosis Tumoral, su purificación y anticuerpos frente a los mismos
US6232446B1 (en) 1989-05-18 2001-05-15 Yeda Research And Development Co. Ltd. TNF ligands
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
US6498237B2 (en) 1989-08-07 2002-12-24 Peptech Limited Tumor necrosis factor antibodies
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
DE59010908D1 (de) * 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
AU646695B2 (en) * 1990-04-09 1994-03-03 Immunex Corporation Isolated viral protein cytokine antagonists
GB2246569A (en) * 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
US20030064480A1 (en) * 1990-06-28 2003-04-03 Leander Lauffer Fusion proteins with immunoglobulin portions, the preparation and use thereof
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
ATE169030T1 (de) * 1990-06-28 1998-08-15 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
AU653937B2 (en) * 1991-04-17 1994-10-20 Medisup International N.V. Water-soluble polypeptides having high affinity for interferons alpha and beta
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
EP0611302B1 (de) * 1991-10-15 2000-03-29 MULLARKEY, Michael F. Rezeptoren zur Behandlung von Entzündungen vom verzögerten Typ
EP0670730B1 (de) * 1992-03-30 2003-06-04 Immunex Corporation Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
EP0639079B1 (de) * 1992-04-30 2000-01-12 Amgen Inc. Methoden zur Behandlung von Interleukin- 1 und - Tumor - Nekrose - Faktor - verursachten Krankheiten
IL101769A (en) * 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action
US20050260201A1 (en) * 1993-01-29 2005-11-24 Centocor, Inc. Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteins
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
IL111125A0 (en) * 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
US6579697B1 (en) * 1995-05-11 2003-06-17 Yeda Research And Development Co. Ltd. Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors
US5741667A (en) * 1994-05-27 1998-04-21 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US7078493B1 (en) 1995-03-15 2006-07-18 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like genes
US8110659B1 (en) 1995-03-15 2012-02-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like genes
US7094564B1 (en) 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US7427492B1 (en) 1995-06-05 2008-09-23 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor receptor-like2
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7070783B1 (en) * 1995-05-09 2006-07-04 The Mathilda And Terence Kennedy Institute Of Rheumatology Small molecular weight TNF receptor multimeric molecule
ZA966663B (en) * 1995-08-17 1998-02-06 Genentech Inc Traf Inhibitors.
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6410252B1 (en) 1995-12-22 2002-06-25 Case Western Reserve University Methods for measuring T cell cytokines
US7357927B2 (en) * 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033904A1 (en) * 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
AU2213697A (en) * 1996-03-18 1997-10-10 Medical Science Systems, Inc. A method for periodontal disease treatment
US5912141A (en) * 1996-05-22 1999-06-15 President & Fellows Of Harvard College Nucleic acids encoding tumor virus susceptibility genes
AU723355B2 (en) 1996-05-23 2000-08-24 Scripps Research Institute, The MHC class II antigen presenting systems and methods for activating CD4+ T cells
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US5939281A (en) * 1996-09-16 1999-08-17 Case Western Reserve University Detecting alloreactivity
EP0961782A4 (de) * 1996-10-30 2003-07-16 Human Genome Sciences Inc Rezeptor tr2 aus der tumornekrosisfaktor-rezeptor-familie.
US6930084B1 (en) 1996-11-06 2005-08-16 The Regents Of The University Of California Treating arthritis with TNF receptor releasing enzyme
US20050191661A1 (en) * 1996-11-06 2005-09-01 Tetsuya Gatanaga Treatment of inflammatory disease by cleaving TNF receptors
NZ335864A (en) 1996-11-06 2001-09-28 Univ California Isolated tumor necrosis factor receptor releasing enzyme (TRRE), compositions comprising the enzyme and methods of the use in modulation of TNF levels
US6593456B1 (en) 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
EP0959897B1 (de) 1996-11-27 2009-04-22 Immunex Corporation Verfahren zur regulierung der stickstoffmonoxid-erzeugung
DK0942740T3 (da) 1996-12-06 2003-12-15 Amgen Inc Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme
CA2273852C (en) 1996-12-06 2009-09-29 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1998054201A1 (en) * 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
AU2472899A (en) * 1998-01-27 1999-08-09 Millennium Pharmaceuticals, Inc. Novel molecules of the tnf receptor superfamily and uses therefor
US20030180310A1 (en) * 1998-04-29 2003-09-25 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US8197430B1 (en) 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US7115557B2 (en) * 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030190669A1 (en) * 1998-12-30 2003-10-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
EP1180159B1 (de) 1999-05-28 2008-09-03 Targeted Genetics Corporation Methoden und zusammensetzungen zur reduktion des tumor-nekrosis-faktor-spiegels (tnf) bei tnf-assoziierten erkrankungen
EP1939300A1 (de) 1999-05-28 2008-07-02 Targeted Genetics Corporation Verfahren und Zusammensetzung zur Senkung des Spiegels des Tumornekrosefaktors (TNF) bei TNF-assoziierten Leiden
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
US7122631B2 (en) * 2000-02-22 2006-10-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU4541101A (en) 2000-03-02 2001-09-12 Xencor Inc Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
CA2423052C (en) 2000-09-22 2011-07-12 Immunex Corporation Screening assays for agonists or antagonists of receptor activator of nf-kb
AU2002256624B2 (en) 2001-02-19 2007-12-06 Merck Patent Gmbh Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
US20030040119A1 (en) * 2001-04-11 2003-02-27 The Regents Of The University Of Michigan Separation devices and methods for separating particles
CA2451955C (en) 2001-06-26 2015-09-29 Abgenix, Inc. Antibodies to opgl
WO2003026695A1 (en) * 2001-09-21 2003-04-03 Genset S.A. Agonists and antagonists of cylixin for the treatment of metabolic disorders
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
PL374311A1 (en) * 2001-12-21 2005-10-03 Immunex Corporation Methods for purifying protein
SI1478394T1 (sl) * 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
WO2003083066A2 (en) 2002-03-27 2003-10-09 Immunex Corporation Methods for increasing polypeptide production
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20080008713A1 (en) * 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
ATE472556T1 (de) * 2002-12-02 2010-07-15 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP2007525188A (ja) 2003-05-16 2007-09-06 インターミューン インコーポレイテッド 合成ケモカイン受容体リガンドおよびその使用方法
US7892563B2 (en) * 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
TW201245229A (en) 2003-10-14 2012-11-16 Hoffmann La Roche Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
JP2008511340A (ja) * 2004-04-30 2008-04-17 バイオフェレシス テクノロジーズ, インコーポレイテッド 患者において可溶性tnfr1、可溶性tnfr2、および可溶性il2を除去する方法およびシステム
CA2576030A1 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7300773B2 (en) * 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
US20070105807A1 (en) * 2005-11-10 2007-05-10 Sazani Peter L Splice switch oligomers for TNF superfamily receptors and their use in treatment of disease
US7785834B2 (en) * 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
US7504106B2 (en) * 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
AU2006344750A1 (en) * 2006-06-15 2007-12-27 Targeted Genetics Corporation Methods for treating target joints in inflammatory arthritis using AAV vectors encoding a TNF antagonist
US20080019970A1 (en) * 2006-07-07 2008-01-24 Gorman James R Methods for preventing, postponing or improving the outcome of spinal device and fusion procedures
US20080075690A1 (en) * 2006-09-22 2008-03-27 Mark Douglas Howell Method for enhancing immune responses in mammals
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US20090264353A1 (en) * 2007-10-19 2009-10-22 Santaris Pharma A/S Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
US8192951B2 (en) 2006-11-03 2012-06-05 Wyeth Llc Glycolysis-inhibiting substances in cell culture
AU2008214359B2 (en) 2007-02-05 2014-01-16 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
RU2009132986A (ru) 2007-03-02 2011-04-10 Уайт (Us) Применение меди и глутамата в культуре клеток для производства полипептидов
WO2009126564A1 (en) 2008-04-07 2009-10-15 Bayer Healthcare Llc Methods of recombinant production of glycoproteins
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CN102770458A (zh) * 2009-12-02 2012-11-07 阿塞勒隆制药公司 用于增加Fc融合蛋白的血清半寿期的组合物和方法
SI3295957T1 (sl) 2010-01-15 2020-02-28 Kirin-Amgen, Inc. Formulacija protitelesa proti IL-17RA in terapevtski režim za zdravljenje luskavice
HRP20191305T1 (hr) 2010-07-09 2019-10-18 Bioverativ Therapeutics Inc. Preradive jednolančane molekule i polipeptidi izrađeni koristeći iste
EP2601287B1 (de) 2010-08-05 2015-01-07 Amgen Inc. Dipeptide zur erhöhung des ertrags und der lebensfähigkeit von zellkulturen
CN102382850A (zh) * 2010-09-01 2012-03-21 山东新时代药业有限公司 新型人肿瘤坏死因子受体-Fc融合基因及其产物蛋白
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
EP2718328A4 (de) 2011-06-08 2014-12-24 Acceleron Pharma Inc Zusammensetzungen und verfahren zur erhöhung der halbwertszeit von serum
KR101662412B1 (ko) 2011-07-01 2016-10-04 암젠 인크 포유동물 세포 배양
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
KR20140058669A (ko) 2011-09-02 2014-05-14 암젠 인크 의약품 및 의약품의 광 노출을 분석하는 방법
US10350139B2 (en) 2011-10-25 2019-07-16 Corning Incorporated Pharmaceutical glass packaging assuring pharmaceutical sterility
US11707408B2 (en) 2011-10-25 2023-07-25 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
AR089231A1 (es) 2011-12-15 2014-08-06 Amgen Inc Metodo de floculacion
AU2013315750B9 (en) 2012-09-11 2018-11-15 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
US20140199728A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
TWI625390B (zh) 2013-03-14 2018-06-01 安美基公司 用於增加重組蛋白質之甘露糖含量之方法
AU2014240596B2 (en) 2013-03-14 2018-09-27 Amgen Inc. Removal of leaked affinity purification ligand
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707153B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717649B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717648B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9713572B2 (en) 2013-04-24 2017-07-25 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707155B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
ES3030960T3 (en) 2013-10-31 2025-07-02 Amgen Inc Use of monensin to regulate glycosylation of recombinant proteins
MX376230B (es) 2014-01-13 2025-03-07 Amgen Inc Regulación del metábolismo de ornitina para manipular el contenido de glicoformas ricas en manosa de proteínas recombinantes.
BR112016017606A2 (pt) 2014-01-29 2017-10-10 Amgen Inc superexpressão de reguladores de via de n-glicosilação para modular a glicosilação de proteínas recombinantes
US10106829B2 (en) 2014-01-29 2018-10-23 Amgen Inc. Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
JP6596014B2 (ja) 2014-03-31 2019-10-23 アムジェン ケー・エー,インコーポレイテッド 爪および頭皮乾癬の治療方法
SG10202113019XA (en) 2014-06-04 2021-12-30 Amgen Inc Methods for harvesting mammalian cell cultures
US11275090B2 (en) 2014-11-19 2022-03-15 Amgen Inc. Quantitation of glycan moiety in recombinant glycoproteins
PL3227454T3 (pl) 2014-12-01 2020-07-27 Amgen Inc. Sposób manipulowania poziomem zawartości glikanów w glikoproteinie
WO2016149139A1 (en) 2015-03-13 2016-09-22 Samsung Bioepis Co., Ltd. Anti-tnf-alpha polypeptide composition and use thereof
ES3064802T3 (en) 2016-10-21 2026-04-29 Amgen Inc Pharmaceutical formulations and methods of making the same
IL321253A (en) 2018-05-01 2025-08-01 Amgen Inc Antibodies with a modulated glycan profile
US11952399B2 (en) 2018-12-18 2024-04-09 Amgen Inc. Methods for purifying proteins
EP4457342A1 (de) 2021-12-29 2024-11-06 Bristol-Myers Squibb Company Erzeugung von landefeldzelllinien
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675285A (en) * 1984-09-19 1987-06-23 Genetics Institute, Inc. Method for identification and isolation of DNA encoding a desired protein
JPS61293924A (ja) * 1985-06-23 1986-12-24 Asahi Chem Ind Co Ltd 生理活性物質の受容タンパク
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5512544A (en) * 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
PT88641B (pt) * 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
EP0721983A1 (de) * 1988-01-22 1996-07-17 ZymoGenetics, Inc. Verfahren zur herstellung von biologisch-aktive Dimerpeptiden
GB8806339D0 (en) * 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
GB8807803D0 (en) * 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
EP0394827A1 (de) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimärische CD4-Immunoglobulin-Polypeptide
DE3922089A1 (de) * 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
ES2072330T5 (es) * 1989-05-18 2013-06-24 Yeda Research And Development Co., Ltd. Proteínas de unión II al Factor de Necrosis Tumoral, su purificación y anticuerpos frente a los mismos
IL95031A (en) * 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
DE59010908D1 (de) * 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
ATE169030T1 (de) * 1990-06-28 1998-08-15 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
GB9022648D0 (en) * 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells

Also Published As

Publication number Publication date
EP0418014B1 (de) 1995-12-20
US5395760A (en) 1995-03-07
DK0418014T3 (da) 1996-01-22
DE69024291D1 (de) 1996-02-01
LU90591I2 (fr) 2000-07-31
ES2080809T4 (es) 2012-12-20
DE10075011I1 (de) 2003-06-12
GR3019333T3 (en) 1996-06-30
USRE36755E (en) 2000-06-27
NL300008I2 (nl) 2000-12-01
ES2080809T3 (es) 1996-02-16
DE69024291T2 (de) 1996-10-31
NL300008I1 (nl) 2000-08-01
DE10075011I2 (de) 2004-08-12
EP0418014A1 (de) 1991-03-20

Similar Documents

Publication Publication Date Title
DE69024291D1 (de) Rezeptoren für Tumornekrosisfaktor-alpha und -beta
CA2065346A1 (en) Tumor necrosis factor-.alpha. and-.beta. receptors
ES2103706T3 (es) Receptores de interleuquina-4.
ATE169956T1 (de) Dna, die für proteine kodiert, die menschliches il-1 binden
DE69132937D1 (de) Typ-II-Interleukin-1-Rezeptoren
DE69016508D1 (de) Interleukin-7-Rezeptoren.
DE3851035D1 (de) Interleukin-7.
HU901326D0 (en) Recombinant protein receptor and process for production thereof
DK0494260T3 (da) Receptorer for granulocytkolonistimulerende faktor
DK256788D0 (da) Mrna-stabilisering i dyreceller